Loading…
Ending the Diagnostic Odyssey Act of 2019
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
63pct
3d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
Ending the Diagnostic Odyssey Act of 2019 This bill allows state Medicaid programs to cover whole genome sequencing services for certain individuals. Specifically, states may cover such services for individuals under the age of 21 (or a lower age, if the state chooses) and for former foster youth under the age of 26 who (1) have been referred or admitted to an intensive care unit or seen by a medical specialist for a suspected genetic or undiagnosed disease, or (2) are suspected by a medical specialist to have a neonatal- or pediatric-onset genetic disease. The Centers for Medicare & Medicaid Services may award grants to assist states in developing plans to cover such services.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (7)
2022 · first_quarter · Health Issues
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Healthcare issues related to clinical laboratories; H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests; Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests; H.R. 6202, the Telehealth Extension Act, and S. 3593, the Telehealth Extension and Evaluation Act, provisions relating to extension of Medicare coverage of telehealth services and limitations on payment for certain laboratory tests; S. 3534, the Tracking Pathogens Act, provisions relating to genomic sequencing of variants of the SARS-CoV-2 virus; S. 3799, the PREVENT Pandemics Act, and a draft of the Improving DATA in Public Health Act, provisions relating to demographic data reporting obligations for laboratories; Federal policy related to the National Correct Coding Initiative and manual instructions inconsistent with American Medical Association guidelines for Current Procedural Terminology (CPT) coding; H.R. 2144, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 4144/S. 2022, the Ending the Diagnostic Odyssey Act, provisions relating to coverage of whole genome sequencing services for certain individuals; H.R. 5030/S. 2706, the DIVERSE Trials Act, provisions relating to enhancing diversity in clinical trials and data collection and reporting by clinical laboratories; Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 6000, the Cures 2.0 Act, provisions relating to pandemic preparedness, improvements in clinical research processes, and advancement of genetic and genomic testing; H.R. 4144/S. 2022, the Ending the Diagnostic Odyssey Act, provisions relating to coverage of whole genome sequencing services for certain individuals; and H.R. 6875, the Right Drug Dose Now Act, provisions relating to use of pharmacogenetic information; H.R. 2565/S. 2952, the FDA Modernization Act, provisions relating to biomedical research; and Federal policy relating to CDC funding for standardization of pediatric reference range intervals and laboratory result harmonization.
Client expense: $280,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Health Issues
Healthcare issues related to clinical laboratories; H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests; Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests; S. 610, the Protecting Medicare and American Farmers from Sequester Cuts Act, provisions relating to delays in data collection and rate changes pertinent to the Medicare Clinical Laboratory Fee Schedule, mitigation of the Medicare sequester and rate changes pertinent to the Medicare Physician Fee Schedule, and suspension of certain statutory pay-as-you-go requirements; S. 701, the Allergy Testing Access Act, provisions relating to Medicare coverage of certain allergy tests; H.R. 2144, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5030/S. 2706, the DIVERSE Trials Act, provisions relating to enhancing diversity in clinical trials and data collection and reporting by clinical laboratories; Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 6000, the Cures 2.0 Act, provisions relating to pandemic preparedness, improvements in clinical research processes, and advancement of genetic and genomic testing; S. 1605, the National Defense Authorization Act for Fiscal Year 2022, provisions relating to TRICARE coverage of preconception and prenatal carrier screening; H.R. 4144/S. 2022, the Ending the Diagnostic Odyssey Act, provisions relating to coverage of whole genome sequencing services for certain individuals; and Federal policy relating to use of pharmacogenetic information, including a discussion draft of the Right Drug Dose Now Act.
Client expense: $840,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2021 · first_quarter · Medicare/Medicaid
(NO BILL #) - ENDING THE DIAGNOSTIC ODYSSEY ACT (fka: HR 4144 & S 3116 - 116TH CONGRESS); ALL PROVISIONS OF THE ACT
Client expense: $290,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care for rare kidney disease; support of telehealth policies for rare disease patients; H.R. 133, Consolidated Appropriations Act of 2021.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Medicare/Medicaid
H.R.4144 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL S.3116 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
Client expense: $270,000 · Firm income: Not reported
Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2020 · fourth_quarter · Health Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement; H.R. 4144/S. 3116, Ending the Diagnostic Odyssey Act of 2019; Public Law 116-136 - CARES Act; Public Law 116-139 - Paycheck Protection Program and Health Care Enhancement Act; H.R. 6800, The Heroes Act; H.R. 925, The Heroes Act; CDC surveillance funding; CURES 2.0 discussion draft; H.R. 133/P.L. 116-260, Consolidated Appropriations Act, 2021
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Medicare/Medicaid
Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services. H.R.4144/S.3116, Ending the Diagnostic Odyssey Act of 2019; Medicaid coverage of whole genome sequencing clinical services.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
Congressional Personalized Medicine Caucus Barriers to Genetic Testing for ALS/Congressional ALS Caucus Briefing H.R. 4393 Advancing Access to Precision Medicine Act H.R. 4144 Ending the Diagnostic Odyssey Act Draft bill Personalizing Medications Act Draft bill Rare Cancer Awareness, Research, and Treatment Act Medicare Coverage of Innovative Technology (MCIT)Pathway CMS Coverage for Minimal Residual Disease Testing CMS National Coverage Analysis for Colorectal Cancer Screening using Blood-Based Biomarker Testing CMS Laboratory Date-of-Service Policy Changes in CY 2021 Hospital OPPS Proposed Rule Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $27,595 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2020 · fourth_quarter · Health Issues
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; H.R. 2507, S. 2158 Newborn Screening Saves Lives Act Reauthorization; FY 2021 CDC Appropriations; HR 4144, Ending the Diagnostic Odyssey Act; H.R. 5062, Advancing Access to Precision Medicine Act; H.R. 4712, S. 3271 Fairness in Orphan Drug Exclusivity Act; H.R. 534, Aidan's Law; HR 6238, Cameron's Law; rare kidney disease issues; HR 133, Consolidated Appropriations Act of 2021
Client expense: $150,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Medicare/Medicaid
H.R.4144 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL S.3116 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
Client expense: $270,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2020 · third_quarter · Health Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement; H.R. 4144/S. 3116, Ending the Diagnostic Odyssey Act of 2019; Public Law 116-136 - CARES Act; Public Law 116-139 - Paycheck Protection Program and Health Care Enhancement Act; H.R. 6800, The Heroes Act; H.R. 925, The Heroes Act; CDC surveillance funding; CURES 2.0 discussion draft
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Health Issues
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care for rare kidney disease; support of telehealth policies for rare disease patients.
Client expense: Not reported · Firm income: $60,000
2020 · third_quarter · Medicare/Medicaid
Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services. H.R.4144/S.3116, Ending the Diagnostic Odyssey Act of 2019; Medicaid coverage of whole genome sequencing clinical services.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Health Issues
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; H.R. 2507, S. 2158 Newborn Screening Saves Lives Act Reauthorization; FY 2021 CDC Appropriations; HR 4144, Ending the Diagnostic Odyssey Act; H.R. 5062, Advancing Access to Precision Medicine Act; H.R. 4712, S. 3271 Fairness in Orphan Drug Exclusivity Act; H.R. 534, Aidan's Law; HR 6238, Cameron's Law; rare kidney disease issues
Client expense: $170,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · second_quarter · Health Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement. H.R. 4144/S. 3116, Ending the Diagnostic Odyssey Act of 2019; Public Law 116-136 - CARES Act; Public Law 116-139 - Paycheck Protection Program and Health Care Enhancement Act; H.R.6800, The Heroes Act; CDC surveillance funding
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Health Issues
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care, for rare kidney disease.
Client expense: Not reported · Firm income: $60,000
2020 · second_quarter · Medicare/Medicaid
H.R.4144 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL S.3116 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
Client expense: $170,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Medicare/Medicaid
Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services. H.R.4144/S.3116, Ending the Diagnostic Odyssey Act of 2019; Medicaid coverage of whole genome sequencing clinical services.
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Health Issues
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; H.R. 2507, S. 2158 Newborn Screening Saves Lives Act Reauthorization; FY 2021 CDC Appropriations; HR 4144, Ending the Diagnostic Odyssey Act; H.R. 5062, Advancing Access to Precision Medicine Act; H.R. 4712, S. 3271 Fairness in Orphan Drug Exclusivity Act; H.R. 534, Aidan's Law; issues related kidney care
Client expense: $150,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · first_quarter · Health Issues
H.R. 748 (P.L. No: 116-136): CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY (CARES) ACT; PROVISIONS RELATED TO CENTERS FOR DISEASE CONTROL AND PREVENTION FUNDING AND NEXT GENERATION SEQUENCING (NGS) & SURVEILLANCE H.R.4144 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 6074 (P.L. No: 116-123) - CORONAVIRUS PREPAREDNESS AND RESPONSE SUPPLEMENTAL APPROPRIATIONS ACT, 2020; PROVISIONS RELATED TO CENTERS FOR DISEASE CONTROL AND PREVENTION FUNDING AND NEXT GENERATION SEQUENCING (NGS) & SURVEILLANCE H.R. 6201 (P.L. No: 116-127): FAMILIES FIRST CORONAVIRUS RESPONSE ACT; PROVISIONS RELATED TO CENTERS FOR DISEASE CONTROL AND PREVENTION FUNDING AND NEXT GENERATION SEQUENCING (NGS) & SURVEILLANCE S.3116 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
Client expense: $180,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Health Issues
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act; Coronavirus Aid, Relief, and Economic Security (CARES) Act - issues concerning rare disease patients; Executive Order regarding Advancing American Kidney Health; issues concerning diagnosis, treatment, patient care, for rare kidney disease.
Client expense: Not reported · Firm income: $60,000
2020 · first_quarter · Health Issues
H.R. 748 (P.L. No: 116-136): CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY (CARES) ACT; PROVISIONS RELATED TO CENTERS FOR DISEASE CONTROL AND PREVENTION FUNDING AND NEXT GENERATION SEQUENCING (NGS) & SURVEILLANCE H.R.4144 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 6074 (P.L. No: 116-123) - CORONAVIRUS PREPAREDNESS AND RESPONSE SUPPLEMENTAL APPROPRIATIONS ACT, 2020; PROVISIONS RELATED TO CENTERS FOR DISEASE CONTROL AND PREVENTION FUNDING AND NEXT GENERATION SEQUENCING (NGS) & SURVEILLANCE H.R. 6201 (P.L. No: 116-127): FAMILIES FIRST CORONAVIRUS RESPONSE ACT; PROVISIONS RELATED TO CENTERS FOR DISEASE CONTROL AND PREVENTION FUNDING AND NEXT GENERATION SEQUENCING (NGS) & SURVEILLANCE S.3116 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
Client expense: $180,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Medicare/Medicaid
Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services. H.R.4144/S.3116, Ending the Diagnostic Odyssey Act of 2019; Medicaid coverage of whole genome sequencing clinical services.
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Health Issues
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; H.R. 2507, S. 2158 Newborn Screening Saves Lives Act Reauthorization; FY 2022 CDC Appropriations; HR 4144, Ending the Diagnostic Odyssey Act; H.R. 5062, Advancing Access to Precision Medicine Act; H.R. 4712, S. 3271 Fairness in Orphan Drug Exclusivity Act; H.R. 534, Aidan's Law
Client expense: $360,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · first_quarter · Health Issues
H.R. 4144/S. 3116, Ending the Diagnostic Odyssey Act of 2019; H.R. 748 (Public Law 116-136), CARES Act - issues related to Next Generation Sequencing (NGS) and surveillance funding
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Health Issues
H.R.4144 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL S.3116 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; ALL PROVISIONS OF THE BILL
Client expense: $190,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Health Issues
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019; H.R. 534, Aidan's Law (newborn screening for ALD); H.R. 5062, Advancing Access to Precision Medicine Act; Kidney disease diagnosis, prevention, and care; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
Client expense: Not reported · Firm income: $60,000
2019 · fourth_quarter · Medicare/Medicaid
Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services. H.R.4144/S.3116, Ending the Diagnostic Odyssey Act of 2019; Medicaid coverage of whole genome sequencing clinical services.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · fourth_quarter · Health Issues
Verifying Accurate Leading-edge IVCT Development (VALID) Act House Discussion Draft 21st Century Cures 2.0 RFI Patient Centered Outcomes Research Institute Reauthorization Congressional Personalized Medicine Caucus H.R. 4144 "Ending the Diagnostic Odyssey Act of 2019" CMS Proposed Decision Memo Coverage of Next Generation Sequencing for Medicare Beneficiaries with Advanced Cancer CMS Oncology Care First Model RFI FDA Activities on Pharmacogenomic Tests Support for FDA Commissioner Nominee Steve Hahn
Client expense: $31,749 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Health Issues
H.R. 4144/S. 3116, Ending the Diagnostic Odyssey Act of 2019
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Health Issues
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; H.R. 2507, S. 2158 Newborn Screening Saves Lives Act Reauthorization; HR 4144, Ending the Diagnostic Odyssey Act; H.R. 5062, Advancing Access to Precision Medicine Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act
Client expense: $170,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · third_quarter · Health Issues
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; Newborn Screening legislation in general; Newborn Screening Saves Lives Reauthorization Act of 2019, H.R. 2507; Lower Health Care Costs Act, S. 1895; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · third_quarter · Health Issues
H.R.4144 - ENDING THE DIAGNOSTIC ODYSSEY ACT OF 2019; PROVISIONS RELATED TO MAKING WHOLE GENOME SEQUENCING MORE ACCESSIBLE AS A DIAGNOSTIC
Client expense: $160,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · third_quarter · Medicare/Medicaid
Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services. H.R.4144, Ending the Diagnostic Odyssey Act of 2019; Medicaid coverage of whole genome sequencing clinical services.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · third_quarter · Health Issues
Verifying Accurate Leading-edge IVCT Development (VALID) Act House Discussion Draft Patient Centered Outcomes Research Institute Reauthorization Congressional Personalized Medicine Caucus H.R.4393 "Advancing Access to Precision Medicine Act" H.R. 4144 "Ending the Diagnostic Odyssey Act of 2019" H.R.3235 "Access to Genetic Counselor Services Act of 2019" S.2543 "Prescription Drug Pricing Reduction Act of 2019" CMS Potential Revisions to Laboratory Date of Service Policy in CY 2020 Hospital Outpatient Prospective Payment System Rule FDA Center for Devices and Radiological Health List of Patient Preference-Sensitive Priorities FDA Activities on Pharmacogenomic Tests Support for full appointment of Acting FDA Commissioner Ned Sharpless
Client expense: $34,864 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2019 · third_quarter · Health Issues
Rare disease patient care, screening, and coverage issues in authorization and appropriations legislation; Orphan Drug Act; HRes 242, Affirming importance of Orphan Drug Act; H.R. 2507, S. 2158 Newborn Screening Saves Lives Act Reauthorization; HR 4144, Ending the Diagnostic Odyssey Act
Client expense: $180,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · third_quarter · Medicare/Medicaid
Policies impacting Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services; H.R. 4144, Ending the Diagnostic Odyssey Act of 2019
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES
| Republican |
| PA |
| Chrissy Houlahan | Democratic | PA |
| Darren Soto | Democratic | FL |
| Eleanor Holmes Norton | Democratic | DC |
| Gus M. Bilirakis | Republican | FL |
| Haley M. Stevens | Democratic | MI |
| Harley Rouda | Democratic | CA |
| J. Luis Correa | Democratic | CA |
| John Shimkus | Republican | IL |
| Josh Harder | Democratic | CA |
| Juan Vargas | Democratic | CA |
| Julia Brownley | Democratic | CA |
| Madeleine Dean | Democratic | PA |
| Pete Aguilar | Democratic | CA |
| Raul Ruiz | Democratic | CA |
| Susan A. Davis | Democratic | CA |
| Tony Cárdenas | Democratic | CA |
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE